SECN 15
Alternative Names: NRP1 antisense oligonucleotide - Secarna Pharmaceuticals; NRP1 targeting antisense oligonucleotide therapeutic - Secarna Pharmaceuticals; SECN-15Latest Information Update: 08 Apr 2025
At a glance
- Originator Secarna Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Gene silencing; Neuropilin 1 expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 26 Mar 2025 Pharmacodynamics data from preclinical studies in Cancer released by Secarna Pharmaceuticals
- 26 Mar 2025 Secarna Pharmaceuticals plans a phase I/II trial for Cancer in mid 2026
- 31 May 2024 Pharmacodynamics data from preclinical studies in Cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)